About The Study:
RSV (Respiratory Syncytial Virus) is a highly prevalent respiratory infection among children, often causing mild cold-like symptoms. However, it can have severe consequences for very young children, older adults, and individuals with weakened immune systems, leading to hospitalizations or even fatalities. In children, RSV can progress to bronchiolitis or pneumonia. Although RSV is typically more common during late fall and winter, there has been a notable increase in cases during atypical months. Unfortunately, there is currently no vaccine available for this age group to prevent RSV, and antibiotics are ineffective since RSV is a viral infection.
This study will last approximately 6 months long and require up to 3 office visits and 2 telephone calls. Compensation of $125 per office visit and $60 per phone call is available for trial-related time. This is an open-label trial and everyone participating will get an active vaccine.
Study-related care is available to participants at no cost and health insurance is not required nor needed.
Qualifications
- Must be between the ages of 2-17 years old
- Parents/Guardians must also be able to attend all study visits
- Generally healthy OR at high risk for RSV infection
- No previous RSV trial participation
- *Please note that other qualifications may apply